Why Halozyme Therapeutics, Inc.’s (HALO) Stock Is Down 13.52%
As of Friday, November 06, Halozyme Therapeutics, Inc.’s HALO share price has dipped by 13.52%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Rosalio Madrigal
Michael Rose
Michael Rose
Michael Rose
| Share Statistics | HALO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11,002.0 | $202.9 | 79% |
|
| Shares Out (Mil) | 122.6 | 55.4 | 66% |
|
| Institutional Ownership | 99.1% | 92.9% | 85% |
|
| Float (Mil) | 112.7 | 40.7 | 63% |
|
| Beta | 0.90 | 1.04 | 53% |
|
| Avg Daily Volume (000s) | 2,565 | 566 | 83% |
|
| Price Change (52-week) |
35.6% | 41.0% | 80% |
|
| Growth | HALO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 39.2% | 13.2% | 93% |
|
| Net Income (5yr) | 19.7% | (10.3%) | 73% |
|
| EPS (5yr) | 23.0% | 15.8% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (3.2%) | (15.7%) | 62% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 5 | |
| Current EPS | $2.634 | $8.887 | $10.592 | |
| Month Ago EPS | $2.641 | $8.837 | $10.679 | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $2.601 | $8.577 | $10.393 | |
| Year/Year Chg | 31.0% | 247.1% | 367.1% | |
| Financials | HALO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,802 | $39 | 58% |
|
| Net Income (TTM) (Mil) | $485 | ($44) | 77% |
|
| EPS (TTM) | $4.159 | ($1.400) | 83% |
|
| Operating Cash Flow (TTM) (Mil) | $898 | ($34) | 79% |
|
| Net Cash Flow (TTM) (Mil) | $611 | ($1) | 92% |
|
| Long-Term Debt (Q1) (Mil) | $2,974 | $4 | 79% |
|
| Enterprise Value (Q1) (Mil) | $14,020 | $144 | 79% |
|
| Valuation | HALO | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 1.97 | na |
|
| P/E | 24.3 | 17.5 | 63% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.1 | 0.8 | 50% |
|
| Ratios | HALO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.0% | 67.6% | 86% |
|
| Net Margin | 26.9% | (50.6%) | 85% |
|
| ROA | 17.0% | (47.4%) | 94% |
|
| ROE | 216.4% | (53.5%) | 98% |
|
| Liabilities to Assets | 101.6% | 29.7% | 95% |
|
| F-Score | 6 | 3 | 67% |
|
Halozyme Therapeutics, Inc. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors